Large cell carcinoma (LCC) is a rare subtype of non-small cell lung cancer (NSCLC) characterized by high prevalence of SMARCA4 deficiency and aggressive clinical behavior.
However, despite these clinical parameters, the benefits of adjuvant therapy in early-stage LCC remain controversial.
